Targazyme snaps up new CEO
Experienced industry executive James Caggiano has been named as the new head of Californian biotech Targazyme, who will take up the mantle of the company’s new Chief Executive Officer.
Caggiano has been working in the industry for almost three decades with particular experience in pharmaceuticals, medical devices, and immuno-oncology.
Over the course of his career, he has worked at big names including Abbott, as a director and later as Vice President of Sales and Marketing, Cardiovascular Devices, and Allergan. During his almost six-year tenure at the latter company, he moved from Vice President, Sales and Marketing, Bariatrics to become General Manager of the firm’s Obesity Business and Medical Devices.
In May 2015 he left Allergan to join Valeant Pharmaceuticals as its President, the same year the company got the green light to acquire Dendreon, a firm which Caggiano had worked for earlier from 2004 to 2008. During his time as Valeant’s President, he led the business turnaround of Dendreon, doubling its value with an ultimate sale of the business to Sanpower for $820 million.
Before his career began in the industry, Caggiano also served as an Armor Officer in the US Army from 1986 to 1990.
“We welcome Jim Caggiano to our Targazyme team and look forward to his leadership with advancing our oncology assets to making a life-changing difference for cancer patients and their families worldwide,” commented Targazyme’s Founder and Executive Chairman Lynnet Koh. “Caggiano brings a track record of delivering major shareholder value through successful execution of sell-side deal transactions and driving major commercial revenue growth. His military leadership skills position the company for consistently delivering on key milestones on time and on budget.”
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
After more than two decades at the head of the company, it has emerged that …